Rachel A. Burga

1.8k total citations
32 papers, 1.5k citations indexed

About

Rachel A. Burga is a scholar working on Immunology, Oncology and Neurology. According to data from OpenAlex, Rachel A. Burga has authored 32 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Immunology, 19 papers in Oncology and 5 papers in Neurology. Recurrent topics in Rachel A. Burga's work include Immune Cell Function and Interaction (17 papers), CAR-T cell therapy research (15 papers) and Immunotherapy and Immune Responses (7 papers). Rachel A. Burga is often cited by papers focused on Immune Cell Function and Interaction (17 papers), CAR-T cell therapy research (15 papers) and Immunotherapy and Immune Responses (7 papers). Rachel A. Burga collaborates with scholars based in United States, China and Mexico. Rachel A. Burga's co-authors include Rohan Fernandes, Carolina Colli Cruz, Catherine M. Bollard, N. Joseph Espat, Mitchell Thorn, Steven C. Katz, Richard P. Junghans, Gary R. Point, Nora M. Haney and Helen H. Lu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Rachel A. Burga

32 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rachel A. Burga United States	19	890	646	518	266	189	32	1.5k
Robert C. Sterner United States	6	1.3k 1.5×	746 1.2×	451 0.9×	616 2.3×	310 1.6×	12	1.9k
Rosalie M. Sterner United States	11	1.4k 1.6×	805 1.2×	492 0.9×	676 2.5×	342 1.8×	22	2.1k
Xin Tang China	17	674 0.8×	399 0.6×	241 0.5×	246 0.9×	208 1.1×	35	1.1k
Bizhi Shi China	28	1.7k 1.9×	1.0k 1.6×	460 0.9×	914 3.4×	305 1.6×	53	2.6k
David Zhang United States	17	431 0.5×	417 0.6×	449 0.9×	484 1.8×	170 0.9×	25	1.3k
Whitney L. Gladney United States	14	1.8k 2.0×	1.2k 1.8×	415 0.8×	584 2.2×	261 1.4×	24	2.4k
Adam Grippin United States	14	463 0.5×	402 0.6×	261 0.5×	362 1.4×	102 0.5×	47	1.1k
Shoubao Ma China	19	592 0.7×	694 1.1×	272 0.5×	769 2.9×	102 0.5×	33	2.0k
Alice A. Tomei United States	17	641 0.7×	492 0.8×	417 0.8×	400 1.5×	291 1.5×	38	1.8k
Jiaqiang Ren United States	26	635 0.7×	443 0.7×	318 0.6×	741 2.8×	177 0.9×	50	1.9k

Countries citing papers authored by Rachel A. Burga

Since Specialization

Citations

This map shows the geographic impact of Rachel A. Burga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel A. Burga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel A. Burga more than expected).

Fields of papers citing papers by Rachel A. Burga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel A. Burga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel A. Burga. The network helps show where Rachel A. Burga may publish in the future.

Co-authorship network of co-authors of Rachel A. Burga

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel A. Burga. A scholar is included among the top collaborators of Rachel A. Burga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel A. Burga. Rachel A. Burga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Burga, Rachel A., Bülent Arman Aksoy, Zheng Ao, et al.. (2025). IL-2-independent expansion, persistence, and antitumor activity in TIL expressing regulatable membrane-bound IL-15. Molecular Therapy. 33(8). 3605–3623. 4 indexed citations

Amaria, Rodabe N., Krishna V. Komanduri, Adam J. Schoenfeld, et al.. (2024). Entering a new era of tumor-infiltrating lymphocyte cell therapy innovation. Cytotherapy. 27(7). 864–873. 2 indexed citations

Burga, Rachel A., Gauri Kulkarni, Zheng Ao, et al.. (2024). Abstract LB072: Tumor-infiltrating lymphocytes (TIL) engineered with membrane-bound IL15 (cytoTIL15 cells) exhibit pharmacologically regulatable signal transduction in cis and trans. Cancer Research. 84(7_Supplement). LB072–LB072. 1 indexed citations

Miska, Jason, Aida Rashidi, Catalina Lee-Chang, et al.. (2021). Polyamines drive myeloid cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma. Science Advances. 7(8). 75 indexed citations

Burga, Rachel A., Kyle D. Pedro, Jacques P. Tremblay, et al.. (2021). 1008P cytoTIL15: A novel TIL therapy for melanoma with superior potency and enhanced persistence without IL2 to improve safety & efficacy and expand patient eligibility. Annals of Oncology. 32. S852–S852. 1 indexed citations

Shukla, Anshi, Juliana Cano‐Mejia, Jaclyn Andricovich, et al.. (2021). An Engineered Prussian Blue Nanoparticles‐Based Nanoimmunotherapy Elicits Robust and Persistent Immunological Memory in a TH‐MYCN Neuroblastoma Model. SHILAP Revista de lepidopterología. 1(8). 21 indexed citations

Lee-Chang, Catalina, Jason Miska, David Hou, et al.. (2020). Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma. The Journal of Experimental Medicine. 218(1). 49 indexed citations

Sweeney, Elizabeth E., Preethi B. Balakrishnan, Allison B. Powell, et al.. (2020). PLGA nanodepots co-encapsulating prostratin and anti-CD25 enhance primary natural killer cell antiviral and antitumor function. Nano Research. 13(3). 736–744. 18 indexed citations

Burga, Rachel A., Eric Yvon, Elizabeth Chorvinsky, et al.. (2019). Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma. Clinical Cancer Research. 25(14). 4400–4412. 69 indexed citations

10.

Patel, Shabnum, Rachel A. Burga, Allison B. Powell, et al.. (2019). Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer. Frontiers in Oncology. 9. 196–196. 46 indexed citations

11.

Burga, Rachel A., Elizabeth Sweeney, Zungho Zun, et al.. (2017). Composite iron oxide–Prussian blue nanoparticles for magnetically guided T<sub>1</sub>-weighted magnetic resonance imaging and photothermal therapy of tumors. International Journal of Nanomedicine. Volume 12. 6413–6424. 32 indexed citations

12.

Yvon, Eric, Rachel A. Burga, Allison B. Powell, et al.. (2017). Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma. Cytotherapy. 19(3). 408–418. 108 indexed citations

13.

Cano‐Mejia, Juliana, Rachel A. Burga, Elizabeth E. Sweeney, et al.. (2016). Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma. Nanomedicine Nanotechnology Biology and Medicine. 13(2). 771–781. 132 indexed citations

14.

Burga, Rachel A., et al.. (2016). Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells. Cytotherapy. 18(11). 1410–1421. 25 indexed citations

15.

Sweeney, Elizabeth E., Rachel A. Burga, Chaoyang Li, Yuan Zhu, & Rohan Fernandes. (2016). Photothermal therapy improves the efficacy of a MEK inhibitor in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Scientific Reports. 6(1). 37035–37035. 29 indexed citations

16.

Katz, Steven C., Rachel A. Burga, Elise McCormack, et al.. (2015). Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases. Clinical Cancer Research. 21(14). 3149–3159. 314 indexed citations

17.

Burga, Rachel A., Mitchell Thorn, Gary R. Point, et al.. (2015). Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunology Immunotherapy. 64(7). 817–829. 186 indexed citations

18.

Saied, Abdul, Lauren A. Licata, Rachel A. Burga, et al.. (2014). Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases. Cancer Gene Therapy. 21(11). 457–462. 35 indexed citations

19.

Katz, Steven C., Rachel A. Burga, Lauren A. Licata, et al.. (2013). Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumor. Journal of Translational Medicine. 11(1). 46–46. 21 indexed citations

20.

Haney, Nora M., et al.. (2012). A functional agarose-hydroxyapatite scaffold for osteochondral interface regeneration. Biomaterials. 33(21). 5247–5258. 126 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact